- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00756379
Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease (Century)
Randomized Trial of Comprehensive Lifestyle Modifications, Optimal Pharmacological Treatment and PET Imaging for Detection and Management of Stable Coronary Artery Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
Advances in diagnostic imaging with expensive technologies and reimbursement policies that favor illness intervention rather than primary and secondary prevention have resulted in rising costs of health care and more people being deprived of its benefits (Sultz 2004, Bodenheimer 2002).
In the field of coronary artery disease (CAD) are several non-invasive imaging techniques for diagnostic and risk stratification purposes such as echocardiography, perfusion imaging (cardiac stress SPECT - single photon emission computed tomography - and stress PET - positron emission tomography), non-invasive cardiac computed tomography angiography (CTA) and combined perfusion-anatomy (PET-CT) studies. There are an estimated 40 million noninvasive cardiac tests performed each year (Mark DB 2003). For echocardiography and SPECT imaging, reimbursement from Medicare encompasses approximately 30% of all payments, totaling over $1 billion in the year 2000 (ACC 2003). There are, however, basic questions about cardiovascular imaging techniques that need to be addressed: how does technology benefit the patient? It is worth the cost? Is treatment plan enhanced? Is outcome better? Data are necessary for addressing these questions and if appropriate for acceptance among practicing physicians, patients and third party insurers.
The relevance of the proposed study, the CENTURY trial, lies in its original design, testing the impact of stress perfusion imaging by PET coupled with two different intensities of clinical management strategies (standard or comprehensive respectively). This study will examine post-test resource utilization and reduction of cardiovascular risk in patients with known disease or at high risk for CAD.
There will be a total of 1300 men and women enrolled with approximately 650 subjects randomized to one of two treatment arms. Eligible patients must have clinical indications for stress perfusion testing.
Following confirmation of eligibility and provision of signed informed consent, patients will be randomized to one of the two possible treatment strategies. At time of randomization patients will be assigned to "PET guided + comprehensive" versus "standard medical treatment."
Patients of both groups will have a baseline myocardial PET perfusion study to quantify the blood flow to the heart muscle, an electrocardiogram, an exercise treadmill stress test to assess exercise tolerance (fitness), a thorough review of the quality of their diet and a complete blood work covering individual lipid profiles. These tests and assessments will be repeated at 2 years and at 5 years.
In addition, subjects assigned to the standard medical management arm will be managed by current standard care provided by their primary referring physician and will be asked to come for clinic study visits annually for 5 years to document their medical and lifestyle management. The PET scan results will be blinded until the end of the study to the standard of care management group.
Subjects enrolled in the comprehensive medical management arm will have the support of a team of professionals focusing on atherosclerotic risk factor modification that involves recommended treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by the primary referring physician.
No experimental medication or procedures will be used. Clinic visits for subject's education and consulting in the comprehensive program will be performed five times during the first year and semiannually thereafter.
At the end of the first 5 years, patients in the "comprehensive" medical management arm will be offered an additional 5-year follow-up at the current study location once a year.
The extended follow-up on cardiovascular or other adverse events for the "current standard of care" group will be based on yearly telephone or mail follow-up.
Both groups will have a full consultation visit, exercise treadmill and dipyridamole PET scan at the end of the total 10 years follow-up, replicating the current initial 5-year follow-up visit protocol.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Weatherhead PET Center, Memorial Hermann Hospital TMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects must be competent to provide written informed consent.
- Subjects must sign an Institutional Review Board (IRB) approved Informed Consent Form (ICF) and HIPAA Authorization prior to the initiation of any study procedures.
Men and women age ≥40
_ Indication for stress perfusion testing
- Appropriate Indications for stress perfusion testing:
- Suspected CAD:
- Men with any chest pain syndrome and two other risk factors
- Women >50 years old with any chest pain syndrome and two other risk factors
- Asymptomatic men and women >50 years with at least three other risk factors* or Coronary Calcium Agatston score >400.
- Diabetic men and women and two other risk factors
- Documented known CAD:
- Men and women asymptomatic or stable symptoms and known CAD by abnormal catheterization or prior SPECT without revascularization after >2 years to evaluate worsening disease or
- Men and women with worsening symptoms and known CAD by abnormal catheterization or prior SPECT/PET without revascularization
- Men and women with chest pain syndrome and previous revascularization
Asymptomatic men and women >5 years after coronary artery bypass graft surgery (CABG) or >2 years after PCI
Risk factors: Diabetes, Current or recent cigarette smoking (within the last 12 months), LDL>130, low HDL <50 women, HDL <45 men, history of metabolic syndrome, hypertension (SPB>140), family history of premature (<60 year) CAD, Atherosclerotic carotid artery disease OR atherosclerotic peripheral vascular disease (APVD) as defined by ankle-brachial index below 0.9 and/or by abnormal duplex ultrasound, CT angiography, magnetic resonance angiography (MRA) or conventional invasive angiogram or previous revascularization procedure.
Framingham's high risk criteria refers to presence of diabetes mellitus with the limitation described above (c) or 10 year absolute Coronary Heart Disease(CHD)risk of >or= 20% (see tables Appendix A).
- Chest pain is defined as Typical Angina if Exertional + Retrosternal + relieved with rest or sublingual nitroglycerin (NTG) , Atypical angina if only two of the above criteria are present and Non-anginal if one or none of the above are present.
Exclusion Criteria:
- Age <40
- Low pretest likelihood of CAD (= not meeting the above criteria)
- Unstable angina high risk (dynamic ST-Twave ECG changes and/or elevated troponin)
- Recent MI (<4 weeks)
- Recent stroke (<4 weeks)
- CABG or percutaneous coronary intervention (PCI) within the last 6 months
- Severe renal dysfunction as defined by creatinine > 2.0 mg/dl
- Active liver disease or hepatic dysfunction, AST or ALT > x 2 the upper limit of normal (ULN)
- Concomitant valvular heart disease
- Left ventricular ejection fraction (LVEF) <30%
- Severe systemic hypertension defined as systolic blood pressure (SBP) > 200 mmHg
- Symptomatic sustained or non-sustained ventricular tachycardia
- Morbid Obesity defined by Body Mass Index > 35
- Sever disability to prevent therapeutic exercise not expected to resolve within 6 months
- Major non-cardiac co-morbidity limiting survival or social situation/condition that in the opinion of the investigator will preclude the patient from participation in the study follow-up.
- Concurrent or prior (within last 30 days) participation in other research studies using investigational drugs or devices.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensive lifestyle modification
P.E.T. guided comprehensive therapy program.
The study intervention is Comprehensive therapy program for risk factor modification.
The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program.
This is in addition to standard current medical therapy as provided by primary physician.
No experimental medications or procedures will be used.
|
Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors.
During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
Other Names:
|
No Intervention: Current standard of care
Current standard of care medical management as provided by primary physician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1.Clinical Endpoints-
Time Frame: 2 years, 5 years and 10 years
|
Average Risk Score modification during 5 year follow-up and major cardiovascular clinical events of death and non-fatal myocardial infarction.
|
2 years, 5 years and 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2. Secondary outcome
Time Frame: 2 years, 5 years and 10 years
|
These measures are major events consisting of death, non-fatal MI, stroke, and revascularization procedures.
|
2 years, 5 years and 10 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comprehensive economic analysis
Time Frame: 2 years, 5 years and 10 years
|
Will compare total cost and health outcomes of treating patients at risk or with established CAD
|
2 years, 5 years and 10 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: K. Lance Gould, MD, University of Texas Medical Health Science Center at Houston
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-08-0312
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Comprehensive therapy program for risk factor modification
-
Dr. Benedict GloverUniversity of Toronto; AbbottUnknownAtrial FibrillationCanada
-
University Hospital, GenevaCompletedChronic Pain | Acute PainSwitzerland
-
Ottawa Hospital Research InstituteThe Physicians' Services Incorporated Foundation; Australian National UniversityCompletedHypertension | Diabetes | Infants Small for Gestational AgeCanada
-
Sherin Hassan Mohammed MehaniCompletedMechanical Ventilation ComplicationEgypt
-
Liberty UniversityNational Academy of Sports MedicineCompletedPostural; DefectUnited States
-
Technische Universität DresdenCharite University, Berlin, Germany; German Federal Ministry of Education and... and other collaboratorsUnknownBipolar DisorderGermany
-
Catharina Ziekenhuis EindhovenRecruitingAtrial Fibrillation | Risk Reduction | Nurse's RoleNetherlands
-
Oslo Metropolitan UniversityNorwegian Labour and Welfare AdministrationCompleted
-
Charles University, Czech RepublicBrno University Hospital; Hospital Podlesi; General Teaching Hospital, Prague; Regional...RecruitingAtrial FibrillationCzechia
-
Umeå UniversityCompleted